Revisiting idiopathic eosinophilic myositis: towards a clinical-pathological continuum from the muscle to the fascia and skin.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
01 06 2023
Historique:
received: 12 05 2022
accepted: 14 09 2022
medline: 5 6 2023
pubmed: 7 10 2022
entrez: 6 10 2022
Statut: ppublish

Résumé

Idiopathic inflammatory myopathies are mainly defined by inflammatory infiltrates within the muscle (lymphocytes and macrophages). Eosinophil muscle infiltration has been described in idiopathic eosinophilic myositis (IEM) and rarely in EF. This study aimed to further delineate the nosological frame of idiopathic eosinophil muscle infiltration through the exhaustive analysis of IEM and EF patients. This multicentre retrospective case series included IEM patients diagnosed between 2000 and 2022. IEM inclusion criteria were eosinophilic muscle infiltration with myositis pathological features, after the exclusion of differential diagnoses. An additional group of EF patients diagnosed between 2016 and 2022 was constituted. Inclusion criteria were an EF diagnosis and fascia thickening with inflammatory infiltrate. A total of 20 IEM cases and 10 EF cases were included. The median (interquartile range) age at diagnosis was 65 (49-70) years; there were 18 males. Data analysis delineated four subgroups: focal EM (FEM, n = 3), diffuse EM (DEM, n = 6), eosinophilic myofasciitis (EMF, n = 11) and EF (n = 10). FEM represented a limited and benign form of myositis. DEM cases presented objective muscle impairment with eosinophilic muscle infiltration. EMF patients presented subjective muscle impairment (myalgia, 55%), fasciitis (on histology and/or imaging), eosinophilic muscle infiltration and frequent hypereosinophilia (55%). EF patients presented myalgia (50%), muscle lesions on histology with fascia-restricted inflammatory infiltrates with (60%) or without (40%) eosinophils. The analysis of IEM and EF patient characteristics delineates four subgroups (FEM, DEM, EMF and EF) in terms of clinical, laboratory, imaging, pathological and outcome specificities, and proposes an adapted diagnostic and care management approach.

Identifiants

pubmed: 36200845
pii: 6749599
doi: 10.1093/rheumatology/keac556
pmc: PMC10234208
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2220-2229

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Références

J Rheumatol. 2003 Aug;30(8):1811-5
pubmed: 12913939
Neuromuscul Disord. 2022 Feb;32(2):116-124
pubmed: 34980535
Trans Assoc Am Physicians. 1975;88:70-86
pubmed: 1224441
J Hand Surg Am. 2015 Apr;40(4):707-10
pubmed: 25747740
Medicine (Baltimore). 1975 Jan;54(1):1-27
pubmed: 1090795
Muscle Nerve. 1990 May;13(5):385-95
pubmed: 2189069
J Allergy Clin Immunol. 2012 Sep;130(3):607-612.e9
pubmed: 22460074
Am J Pathol. 1979 Aug;96(2):493-518
pubmed: 474708
Neurology. 2003 Aug 12;61(3):288-9
pubmed: 12913184
Clin Rheumatol. 2015 Aug;34(8):1481-4
pubmed: 25245261
Ann Neurol. 1977 Jan;1(1):65-71
pubmed: 889290
Eur Radiol. 1999;9(3):525-8
pubmed: 10087128
Eur Respir Rev. 2022 Jan 25;31(163):
pubmed: 35082127
Arch Dermatol. 1997 Feb;133(2):203-6
pubmed: 9041834
Arthritis Rheum. 1993 Jul;36(7):1014-24
pubmed: 8318029
Blood Rev. 2021 Sep;49:100809
pubmed: 33714638
Presse Med. 2011 Apr;40(4 Pt 2):e209-18
pubmed: 21376512
Ann Intern Med. 1982 Jul;97(1):78-92
pubmed: 7046556
Autoimmun Rev. 2014 Apr-May;13(4-5):375-8
pubmed: 24424174
Autoimmun Rev. 2014 Apr-May;13(4-5):379-82
pubmed: 24424187
Clin Dermatol. 2018 Jul - Aug;36(4):487-497
pubmed: 30047432
J Rheumatol. 1989 Oct;16(10):1364-5
pubmed: 2810263
J Clin Pathol. 2009 May;62(5):442-7
pubmed: 19139036

Auteurs

Cécile Fermon (C)

Service de Médecine Interne, Centre Hospitalier Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Lola E R Lessard (LER)

Service d'Electroneuromyographie et Pathologies Neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
Laboratoire Physiopathologie et Génétique du Neurone et du Muscle (PGNM), CNRS UMR5261-INSERM U1315, Institut NeuroMyoGène-Université Claude Bernard Lyon 1, Lyon, France.

Tanguy Fenouil (T)

Service de Cytologie et d'Anatomie Pathologique, Département de Neuropathologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.

Alain Meyer (A)

Centre de Reference des Maladies Autoimmunes Rares, Service de Rhumatologie, Exploration Fonctionnelle Musculaires, Service de Physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
EA3072 Université de Strasbourg, Strasbourg, France.

Marie Faruch-Bilfeld (M)

Service d'Imagerie, Centre Hospitalier Universitaire de Toulouse, Hôpital Pierre Paul Riquet, Toulouse, France.

Marie Robert (M)

Service de Médecine Interne, Centre Hospitalier Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Verena Landel (V)

Direction de la Recherche en Santé, Hospices Civils de Lyon, Lyon, France.

Arnaud Hot (A)

Service de Médecine Interne, Centre Hospitalier Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

François-Jérôme Authier (FJ)

Université Paris Est-Créteil, INSERM, IMRB U955, Team Relaix, Créteil, France.
Centre de Référence « Nord-Est-Ile de France » pour les Pathologies Neuromusculaires, FILNEMUS, Paris, France.
UH Histologie/Département de Pathologie, Centre Hospitalier Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France.

Nathalie Streichenberger (N)

Laboratoire Physiopathologie et Génétique du Neurone et du Muscle (PGNM), CNRS UMR5261-INSERM U1315, Institut NeuroMyoGène-Université Claude Bernard Lyon 1, Lyon, France.
Service de Cytologie et d'Anatomie Pathologique, Département de Neuropathologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Lyon, France.

Laure Gallay (L)

Service de Médecine Interne, Centre Hospitalier Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France.
Laboratoire Physiopathologie et Génétique du Neurone et du Muscle (PGNM), CNRS UMR5261-INSERM U1315, Institut NeuroMyoGène-Université Claude Bernard Lyon 1, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH